Published in Nat Rev Drug Discov on May 01, 2013
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med (2015) 1.74
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol (2014) 1.43
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat Commun (2017) 1.42
Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer (2015) 1.24
Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet (2014) 1.17
Patient-centric trials for therapeutic development in precision oncology. Nature (2015) 1.14
Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol (2014) 1.12
Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther (2013) 1.10
Next-generation sequencing in the clinic. Nat Biotechnol (2013) 1.09
Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. Elife (2014) 1.01
Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing. Hum Mutat (2015) 1.00
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS One (2014) 0.97
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Cancer biomarker discovery and validation. Transl Cancer Res (2015) 0.96
Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol (2016) 0.96
Precision medicine in diffuse large B-cell lymphoma: hitting the target. Haematologica (2015) 0.95
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol (2014) 0.92
Modeling cancer metabolism on a genome scale. Mol Syst Biol (2015) 0.92
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget (2015) 0.90
Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers (Basel) (2014) 0.90
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J Natl Cancer Inst (2015) 0.90
Managing incidental genomic findings in clinical trials: fulfillment of the principle of justice. PLoS Med (2014) 0.89
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget (2015) 0.88
High-Performance Integrated Virtual Environment (HIVE) Tools and Applications for Big Data Analysis. Genes (Basel) (2014) 0.87
Application of molecular profiling in clinical trials for advanced metastatic cancers. J Natl Cancer Inst (2015) 0.87
Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT Pharmacometrics Syst Pharmacol (2014) 0.87
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Front Oncol (2014) 0.85
Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One (2014) 0.85
Mast cells as a potential prognostic marker in prostate cancer. Dis Markers (2013) 0.84
Biological data sciences in genome research. Genome Res (2015) 0.83
Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer (2016) 0.82
Personalized targeted therapy for esophageal squamous cell carcinoma. World J Gastroenterol (2015) 0.82
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. J Transl Med (2015) 0.81
The present and future of genome editing in cancer research. Hum Genet (2016) 0.81
Next-generation sequencing: hype and hope for development of personalized radiation therapy? Radiat Oncol (2015) 0.80
New concepts in breast cancer genomics and genetics. Breast Cancer Res (2014) 0.79
GeneMed: An Informatics Hub for the Coordination of Next-Generation Sequencing Studies that Support Precision Oncology Clinical Trials. Cancer Inform (2015) 0.79
Use of biomarkers in ALS drug development and clinical trials. Brain Res (2014) 0.79
Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods. J Mol Diagn (2016) 0.79
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. Genome Biol (2016) 0.79
European Medicines Agency initiatives and perspectives on pharmacogenomics. Br J Clin Pharmacol (2014) 0.79
Transcriptome Analysis of CD4+ T Cells in Coeliac Disease Reveals Imprint of BACH2 and IFNγ Regulation. PLoS One (2015) 0.79
Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics. Oncotarget (2016) 0.78
Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors. PLoS One (2016) 0.78
Challenges in identifying cancer genes by analysis of exome sequencing data. Nat Commun (2016) 0.77
Boosting for high-dimensional two-class prediction. BMC Bioinformatics (2015) 0.77
Multitask learning improves prediction of cancer drug sensitivity. Sci Rep (2016) 0.77
Next-Generation Sequencing to Guide Clinical Trials. Clin Cancer Res (2015) 0.76
From Molecules to Patients: The Clinical Applications of Translational Bioinformatics. Yearb Med Inform (2015) 0.76
Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers. CPT Pharmacometrics Syst Pharmacol (2015) 0.76
Precision medicine for advanced prostate cancer. Curr Opin Urol (2016) 0.76
A new molecular signature method for prediction of driver cancer pathways from transcriptional data. Nucleic Acids Res (2016) 0.75
Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. PLoS One (2017) 0.75
Integrating precision cancer medicine into healthcare-policy, practice, and research challenges. Genome Med (2016) 0.75
A Scalable Data Access Layer to Manage Structured Heterogeneous Biomedical Data. PLoS One (2016) 0.75
Targeted pharmacotherapy after somatic cancer mutation screening. F1000Res (2016) 0.75
Pragmatic medicine in solid cancer: a translational alternative to precision medicine. Onco Targets Ther (2016) 0.75
Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study. Br J Cancer (2016) 0.75
Mung bean nuclease treatment increases capture specificity of microdroplet-PCR based targeted DNA enrichment. PLoS One (2014) 0.75
Integrative network modeling approaches to personalized cancer medicine. Per Med (2015) 0.75
The Use of Non-Variant Sites to Improve the Clinical Assessment of Whole-Genome Sequence Data. PLoS One (2015) 0.75
Towards precision medicine: discovering novel gynecological cancer biomarkers and pathways using linked data. J Biomed Semantics (2017) 0.75
Noncoding RNAs as effective markers in cancer-care management. Nat Med (2017) 0.75
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 3.14
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice. Blood (2004) 1.52
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res (2004) 1.04
Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood (2004) 1.03
Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood (2006) 0.93